T1	Outcomes 246 293	lung function, exacerbations, and health status
T2	Outcomes 733 741	Efficacy
T3	Outcomes 752 877	rate of decline in FEV(1) after the bronchodilator and in health status, frequency of exacerbations, respiratory withdrawals.
T4	Outcomes 895 961	morning serum cortisol concentration, incidence of adverse events.
T5	Outcomes 980 1005	no significant difference
T6	Outcomes 1013 1054	annual rate of decline in FEV(1 )(P=0.16)
T7	Outcomes 1056 1067	Mean FEV(1)
T8	Outcomes 1098 1118	significantly higher
T9	Outcomes 1201 1225	Median exacerbation rate
T10	Outcomes 1230 1237	reduced
T11	Outcomes 1330 1356	Health status deteriorated
T12	Outcomes 1447 1458	Withdrawals
T13	Outcomes 1651 1676	rate of decline in FEV(1)
T14	Outcomes 1685 1720	produce a small increase in FEV(1).
T15	Outcomes 1766 1779	exacerbations
T16	Outcomes 1786 1818	slower decline in health status.
